Clinical Microbiology and Infection

Slides:



Advertisements
Similar presentations
Microbial culturomics: paradigm shift in the human gut microbiome study J.-C. Lagier, F. Armougom, M. Million, P. Hugon, I. Pagnier, C. Robert, F. Bittar,
Advertisements

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Laboratory diagnosis and biosafety issues of biological warfare agents
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
J.-C. Lagier  Clinical Microbiology and Infection 
The potential beneficial role of faecal microbiota transplantation in diseases other than Clostridium difficile infection  R. Singh, M. Nieuwdorp, I.J.M.
Benchmarking inappropriate empirical antibiotic treatment
Gut bacterial microbiota and obesity
Approach to diagnosis of infective endocarditis
O.J. Dyar, G. Tebano, C. Pulcini  Clinical Microbiology and Infection 
S. Wagenpfeil, A. Neiss, K. Banz, P. Wutzler 
Changes in the intestinal microbiota from adulthood through to old age
Herpes zoster in non-hospitalized children
Migrant health—a cause for concern?
Invasive group A, B, C and G streptococcal infections in Denmark 1999–2002: epidemiological and clinical aspects  K. Ekelund, P. Skinhøj, J. Madsen, H.B.
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
J.-P. Van geertruyden  Clinical Microbiology and Infection 
Virological tools to diagnose and monitor hepatitis C virus infection
R. Cantón  Clinical Microbiology and Infection 
P. Nordmann, L. Poirel  Clinical Microbiology and Infection 
A.E. Muller, U. Theuretzbacher, J.W. Mouton 
Louis Pasteur, from crystals of life to vaccination
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
Surveillance of Legionnaires’ disease in Austria
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
Impact of antibiotic restrictions: the pharmaceutical perspective
Vector control: a cornerstone in the malaria elimination campaign
Training for the infectious diseases speciality in Norway
Laboratory diagnosis and biosafety issues of biological warfare agents
CMI editorial report 2011 Clinical Microbiology and Infection
C. Fabrizio, A. Procopio  Clinical Microbiology and Infection 
Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice  J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman  Clinical.
Elements of design: the knowledge on which we build
Levofloxacin in the treatment of ventilator-associated pneumonia
G. Pappas  Clinical Microbiology and Infection 
R. Bitterman, M. Paul, D. Polak, Y. Geffen 
Metagenomics and probiotics
Effect of antioxidants on the immune response of Helicobacter pylori
Laboratory diagnosis of Clostridium difficile disease
The practice of travel medicine in Europe
Pathogenesis of catheter-related infections: lessons for new designs
T.M. File  Clinical Microbiology and Infection 
Antibacterial drug discovery in the 21st century
Abstracts cont. Clinical Microbiology and Infection
Pandemic lineages of extraintestinal pathogenic Escherichia coli
Benchmarking inappropriate empirical antibiotic treatment
Effect of metronidazole versus standard care on length of stay of patients admitted with severe infectious mononucleosis: a randomized controlled trial 
Current experience in treating invasive zygomycosis with posaconazole
Reducing antibiotic use in influenza: challenges and rewards
A.P. Underwood, J. Green  Clinical Microbiology and Infection 
Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan  Y.-C. Hsieh, L.-Y. Chang, Y.-C. Huang, H.-C. Lin,
An after-hours clinical liaison blood culture service—is it worth it?
Statin use and clinical outcomes among pneumonia patients
Clinical Microbiology and Infection
I. Bitar, A. Piazza  Clinical Microbiology and Infection 
Clinical Microbiology and Infection
K. Kaier, N.T. Mutters, U. Frank  Clinical Microbiology and Infection 
Z. Erjavec, H. Kluin-Nelemans, P.E. Verweij 
The atypical pneumonias: clinical diagnosis and importance
Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe  Robert D. Fox  Clinical Microbiology.
Abstracts Clinical Microbiology and Infection
Modelling during an emergency: the 2009 H1N1 influenza pandemic
A. Manzur, F. Gudiol  Clinical Microbiology and Infection 
J.L. Balcázar  Clinical Microbiology and Infection 
G.C. Schito  Clinical Microbiology and Infection 
J.A. Pérez-Molina, F. Fernández  Clinical Microbiology and Infection 
Impact of antibiotic restrictions: the patient's perspective
Comparative study of pediculicidal effect of medical plants
CMI readers' survey Clinical Microbiology and Infection
The future of diagnostic bacteriology
Presentation transcript:

Clinical Microbiology and Infection Crosstalk between the gut microbiota and the endocannabinoid system: impact on the gut barrier function and the adipose tissue  P.D. Cani  Clinical Microbiology and Infection  Volume 18, Pages 50-53 (July 2012) DOI: 10.1111/j.1469-0691.2012.03866.x Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 The gut microbiota and the endocannabinoid system: impact of prebiotic-induced changes in the gut microbiota. (a) Obesity (nutritional or genetic) is associated with changes in the gut microbiota composition. In this pathophysiological situation, the endocannabinoid system tone is found to be overactive in the colon and in the adipose tissue (higher NAPE-PLD mRNA, CBI mRNA expression and N-arachidonoylethanolamine tissue content, lower FAAH mRNA expression). This phenomenon is associated with the development of gut permeability, metabolic endotoxaemia and with altered adipose tissue metabolism (adipogenesis). (b) Prebiotic (oligofructose) treatment profoundly changes the gut microbiota composition as described in [14], leading to a decreased endocannabinoid system tone in the targeted tissues (e.g. colon and adipose tissue), thereby counteracting gut permeability and metabolic endotoxaemia. Clinical Microbiology and Infection 2012 18, 50-53DOI: (10.1111/j.1469-0691.2012.03866.x) Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions